Should I buy or sell Neuronetics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" STIM shares. View STIM analyst ratings or view top-rated stocks .

What is Neuronetics' stock price target for 2024?

2 equities research analysts have issued 12 month target prices for Neuronetics' shares. Their STIM share price targets range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 110.5% from the stock's current price. View analysts price targets for STIM or view top-rated stocks among Wall Street analysts .

How have STIM shares performed in 2024?

Neuronetics' stock was trading at $2.90 on January 1st, 2024. Since then, STIM stock has increased by 31.0% and is now trading at $3.80. View the best growth stocks for 2024 here .

Are investors shorting Neuronetics?

Neuronetics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 94,600 shares, an increase of 77.8% from the March 15th total of 53,200 shares. Based on an average trading volume of 199,100 shares, the days-to-cover ratio is presently 0.5 days. View Neuronetics' Short Interest .

When is Neuronetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our STIM earnings forecast .

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) released its earnings results on Tuesday, March, 5th. The company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.07. The company earned $20.31 million during the quarter, compared to analyst estimates of $19.73 million. Neuronetics had a negative net margin of 42.31% and a negative trailing twelve-month return on equity of 72.76%. During the same quarter last year, the firm earned ($0.30) EPS.

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics issued an update on its first quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $16.7 million-$17.7 million, compared to the consensus revenue estimate of $17.0 million.

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX) , Inovio Pharmaceuticals (INO) , Novavax (NVAX) , Gilead Sciences (GILD) , iBio (IBIO) , Onconova Therapeutics (ONTX) , Pfizer (PFE) , Tonix Pharmaceuticals (TNXP) , Vaxart (VXRT) and Acasti Pharma (ACST) .

When did Neuronetics IPO?

Neuronetics (STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Who are Neuronetics' major shareholders?

Neuronetics' stock is owned by many different retail and institutional investors. Top institutional investors include David J Yvars Group (0.23%). Insiders that own company stock include Bruce Joseph Shook , Cannell Capital Llc, Keith J Sullivan , Paul Liberman, Robert Cascella , Sheryl L Conley , Stephen Furlong and William Andrew Macan . View institutional ownership trends .

How do I buy shares of Neuronetics?

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:STIM

Neuronetics (STIM) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free STIM Stock Alerts

$3.80

-0.03 (-0.78%)

(As of 04/19/2024 ET)

Compare

Today's Range: $3.76
▼
$4.04
50-Day Range: $2.79
▼
$4.81
52-Week Range: $1.03
▼
$5.07

Volume: 48,572 shs
Average Volume: 189,296 shs
Market Capitalization: $113.92 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Get Neuronetics alerts:

Neuronetics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 110.5% Upside
$8.00 Price Target
Short Interest: Healthy
0.32% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$489,167 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.92) to ($0.62) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.88 out of 5 stars

Medical Sector

597th out of 911 stocks

Surgical & Medical Instruments Industry

66th out of 97 stocks

3.3

Analyst's Opinion

Consensus Rating
Neuronetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Neuronetics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.32% of the outstanding shares of Neuronetics have been sold short.
Short Interest Ratio / Days to Cover
Neuronetics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Neuronetics has recently increased by 77.82%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Neuronetics does not currently pay a dividend.
Dividend Growth
Neuronetics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for STIM.

2.1

News and Social Media Coverage

News Sentiment
Neuronetics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
Search Interest
Only 5 people have searched for STIM on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Neuronetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $489,167.00 in company stock.
Percentage Held by Insiders
Only 7.30% of the stock of Neuronetics is held by insiders.
Percentage Held by Institutions
53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Neuronetics are expected to grow in the coming year, from ($0.92) to ($0.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Neuronetics is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Neuronetics is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Neuronetics has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Neuronetics Stock (NASDAQ:STIM)

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

STIM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

STIM Stock News Headlines

April 12, 2024 | msn.com

New Study Offers Hope for Depression Patients Undergoing TMS Therapy

April 10, 2024 | globenewswire.com

New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 5, 2024 | benzinga.com

Neuronetics Stock (NASDAQ:STIM), Quotes and News Summary

April 1, 2024 | msn.com

Neuronetics Bolsters Talent Pool with Strategic Stock Incentives for New Hires

March 29, 2024 | msn.com

FDA Clears NeuroStar's TMS Therapy for Adolescents with Major Depressive Disorder

March 27, 2024 | finance.yahoo.com

Neuronetics wins FDA clearance for device to treat adolescents with depression

March 27, 2024 | finance.yahoo.com

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 27, 2024 | globenewswire.com

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 27, 2024 | markets.businessinsider.com

Buy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD Market

March 25, 2024 | msn.com

Neuronetics’s NeuroStar wins FDA clearance for adolescents with depression

March 25, 2024 | finanznachrichten.de

Neuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression

March 25, 2024 | marketwatch.com

Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21

March 25, 2024 | markets.businessinsider.com

Neuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New Indication

March 25, 2024 | globenewswire.com

NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression

March 16, 2024 | finance.yahoo.com

STIM Apr 2024 5.000 put

March 12, 2024 | msn.com

Neuronetics and Transformations Care Network Join Forces to Expand Availability of Innovative Depression Treatment

March 7, 2024 | seekingalpha.com

Neuronetics, Inc. (STIM) Q4 2023 Earnings Call Transcript

March 7, 2024 | finance.yahoo.com

Neuronetics Inc (STIM) Reports Record Revenues in Q4 and Full Year 2023

March 7, 2024 | finance.yahoo.com

Neuronetics, Inc. (NASDAQ:STIM) Q4 2023 Earnings Call Transcript

March 7, 2024 | globenewswire.com

Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network

March 6, 2024 | msn.com

Neuronetics GAAP EPS of -$0.19 beats by $0.07, revenue of $20.31M beats by $0.31M

March 6, 2024 | finance.yahoo.com

Neuronetics Full Year 2023 Earnings: US$1.05 loss per share (vs US$1.38 loss in FY 2022)

March 5, 2024 | finance.yahoo.com

Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results

March 5, 2024 | globenewswire.com

Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results

March 4, 2024 | msn.com

Neuronetics Q4 2023 Earnings Preview

See More Headlines

Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:STIM
CUSIP: N/A
CIK: 1227636
Web: www.neurostar.com
Phone: (610) 640-4202
Fax: 610-640-4206
Employees: 203
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $8.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +101.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.07)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,190,000.00
Net Margins: -42.31%
Pretax Margin: -42.31%
Return on Equity: -72.76%
Return on Assets: -29.25%

Debt

Debt-to-Equity Ratio: 1.73
Current Ratio: 4.73
Quick Ratio: 4.33

Sales & Book Value

Annual Sales: $71.35 million
Price / Sales: 1.67
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.18 per share
Price / Book: 3.36

Miscellaneous

Outstanding Shares: 29,980,000
Free Float: 27,787,000
Market Cap: $119.02 million
Optionable: Optionable
Beta: 2.44

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Keith J. Sullivan (Age 66)
President, CEO & Director
Comp: $1.39M
Mr. Stephen J. Furlong M.S. (Age 60)
Executive VP, CFO & Treasurer
Comp: $771.38k
Mr. W. Andrew Macan (Age 51)
Executive VP, GC, Chief Compliance Officer & Corporate Secretary
Comp: $629.7k
Mr. Rusty Page
Senior VP of Operations & Quality
Ms. Lisa Metzner-Rosas
Senior VP & Chief Marketing Officer
Ms. Sara Grubbs
Senior VP & Chief Revenue Officer
Mr. Rick Grubbs
Senior Vice President of National Accounts
Mr. Cory S. Anderson
Senior Vice President of R&D and Clinical

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STIM Stock Analysis - Frequently Asked Questions

Should I buy or sell Neuronetics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" STIM shares.
View STIM analyst ratings or view top-rated stocks.
What is Neuronetics' stock price target for 2024?: 2 equities research analysts have issued 12 month target prices for Neuronetics' shares. Their STIM share price targets range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 110.5% from the stock's current price.
View analysts price targets for STIM or view top-rated stocks among Wall Street analysts.
How have STIM shares performed in 2024?: Neuronetics' stock was trading at $2.90 on January 1st, 2024. Since then, STIM stock has increased by 31.0% and is now trading at $3.80.
View the best growth stocks for 2024 here.
Are investors shorting Neuronetics?: Neuronetics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 94,600 shares, an increase of 77.8% from the March 15th total of 53,200 shares. Based on an average trading volume of 199,100 shares, the days-to-cover ratio is presently 0.5 days.
View Neuronetics' Short Interest.
When is Neuronetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our STIM earnings forecast.
How were Neuronetics' earnings last quarter?: Neuronetics, Inc. (NASDAQ:STIM) released its earnings results on Tuesday, March, 5th. The company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.07. The company earned $20.31 million during the quarter, compared to analyst estimates of $19.73 million. Neuronetics had a negative net margin of 42.31% and a negative trailing twelve-month return on equity of 72.76%. During the same quarter last year, the firm earned ($0.30) EPS.

What guidance has Neuronetics issued on next quarter's earnings?: Neuronetics issued an update on its first quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $16.7 million-$17.7 million, compared to the consensus revenue estimate of $17.0 million.
What other stocks do shareholders of Neuronetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).
When did Neuronetics IPO?: Neuronetics (STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.
Who are Neuronetics' major shareholders?: Neuronetics' stock is owned by many different retail and institutional investors. Top institutional investors include David J Yvars Group (0.23%). Insiders that own company stock include Bruce Joseph Shook, Cannell Capital Llc, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong and William Andrew Macan.
View institutional ownership trends.
How do I buy shares of Neuronetics?: Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:STIM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial